Deborah Rathjen, B.Sc. (Hons), Ph.D., MAICD, FTSE, has been appointed as chair of the board of directors of Bioasis. She takes over from former board chair and chief executive officer Rob Hutchison, who retired. “We are absolutely delighted that Dr. Rathjen is the new chair of our board,” said Mark Day, Ph.D., president and chief executive officer, Bioasis … more
The company has also appointed Caroline Hill, Ph.D., senior vice president, head of research and development operations. “The addition of Caroline further illustrates our ability to attract top talent to the Bioasis team,” said Dr. Day … more
Bioasis is a biopharmaceutical company with a proprietary blood-brain barrier platform delivery technology focused on development of therapeutics for the treatment of brain cancers and neurodegenerative diseases.